Table 2.

Description of the symptoms presented during the first 14 days of follow-up to adults over 40 years of age who came to be vaccinated with the fourth dose against COVID-19 in Trujillo, Peru (N = 411).

	Day 3		Day 7		p-Value *	Day 14		p-Value ±
	N°	%	N°	%		N°	%
They presented adverse effects					0.025			<0.001
Only on the arm	113	27.5	35	8.5		14	3.4
Systemic level only	28	6.8	26	6.3		10	2.4
Both	216	52.6	20	4.9		2	0.5
None	54	13.1	330	80.3		385	93.7
Number of adverse effects in the arm					0.321			<0.001
0	82	20	356	86.6		395	96.1
1	251	61.1	50	12.2		16	3.9
2 or more	78	18.9	5	1.2		0	0
Adverse effects on the arm					<0.001			<0.001
Injection site pain	323	78.6	49	11.9		15	3.7
Swelling at the injection site	71	17.3	3	0.8		0	0
Swelling in the armpit, close to the injection area	9	2.2	1	0.3		0	0
Another reaction	11	2.7	7	1.7		1	0.2
Number of systemic adverse effects					<0.001			<0.001
0	167	40.6	365	88.8		399	97
1	82	20	18	4.4		6	1.5
2 or more	162	39.4	28	6.8		6	1.5
Systemic adverse effects					<0.001			<0.001
Fatigue	82	20	8	2		2	0.5
Headache	84	20.5	12	2.9		4	1
Muscle pain	113	27.5	11	2.7		2	0.5
Fever above 38 °C	28	6.8	2	0.5		0	0
Fever less than 38 °C	52	12.7	3	0.7		0	0
Nausea/vomiting	13	3.2	2	0.5		0	0
Diarrhea	13	3.2	2	0.5		0	0
General discomfort	137	33.3	11	2.7		1	0.2
Widespread rash	0	0	1	0.2		1	0.2
Rash on the face	0	0	1	0.2		1	0.2
Chest pain	16	3.9	5	1.2		2	0.5
Irregular pulse	12	2.9	0	0		0	0
Difficulty breathing	11	2.7	0	0		0	0
Drowsiness	13	3.2	2	0.5		2	0.5
Another reaction	47	11.4	21	5.1		5	1.2

* Difference obtained from comparing day 7 to day 3. ± Difference obtained from comparing day 14 to day 3.